Trade Galectin Therapeutics Inc. - GALT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Long position overnight fee | -0.0225% |
| Short position overnight fee | -0.0219% |
| Overnight fee time | 21:00 (UTC) |
| Min traded quantity | 1 |
| Currency | USD |
| Margin | 20% |
| Stock exchange | United States of America |
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 2 |
| Open* | 1.93 |
| Day's Range* | 1.93 - 1.93 |
| 1-Year Change* | -3.98% |
| Volume | N/A |
| Average Vol. (3m) | 2.01397 |
| 52 wk Range | N/A |
| Market Cap | 119.074 |
| P/E Ratio | N/A |
| Shares Outstanding | 59388500 |
| Revenue | N/A |
| EPS | -0.5802 |
| Dividend (Yield %) | N/A |
| Beta | 1.88773 |
| Next Earnings Date | Aug 15, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 11, 2022 | 2.00 | 0.07 | 3.63% | 1.93 | 2.01 | 1.92 |
| Aug 10, 2022 | 1.97 | 0.07 | 3.68% | 1.90 | 2.03 | 1.90 |
| Aug 9, 2022 | 1.91 | -0.15 | -7.28% | 2.06 | 2.08 | 1.88 |
| Aug 8, 2022 | 2.12 | -0.02 | -0.93% | 2.14 | 2.21 | 2.08 |
| Aug 5, 2022 | 2.15 | -0.06 | -2.71% | 2.21 | 2.22 | 2.10 |
| Aug 4, 2022 | 2.13 | 0.01 | 0.47% | 2.12 | 2.17 | 2.09 |
| Aug 3, 2022 | 2.14 | -0.05 | -2.28% | 2.19 | 2.25 | 2.13 |
| Aug 2, 2022 | 2.19 | -0.01 | -0.45% | 2.20 | 2.25 | 2.19 |
| Aug 1, 2022 | 2.23 | -0.02 | -0.89% | 2.25 | 2.26 | 2.21 |
| Jul 29, 2022 | 2.22 | -0.28 | -11.20% | 2.50 | 2.52 | 2.19 |
| Jul 28, 2022 | 2.45 | 0.36 | 17.22% | 2.09 | 2.45 | 2.08 |
| Jul 27, 2022 | 2.05 | -0.05 | -2.38% | 2.10 | 2.14 | 2.03 |
| Jul 26, 2022 | 1.99 | -0.20 | -9.13% | 2.19 | 2.20 | 1.98 |
| Jul 25, 2022 | 2.10 | 0.22 | 11.70% | 1.88 | 2.16 | 1.84 |
| Jul 22, 2022 | 1.82 | 0.09 | 5.20% | 1.73 | 1.83 | 1.73 |
| Jul 21, 2022 | 1.73 | 0.03 | 1.76% | 1.70 | 1.73 | 1.70 |
| Jul 20, 2022 | 1.72 | 0.07 | 4.24% | 1.65 | 1.77 | 1.65 |
| Jul 19, 2022 | 1.65 | 0.05 | 3.12% | 1.60 | 1.67 | 1.60 |
| Jul 18, 2022 | 1.59 | 0.02 | 1.27% | 1.57 | 1.62 | 1.57 |
| Jul 15, 2022 | 1.63 | -0.03 | -1.81% | 1.66 | 1.67 | 1.57 |
Galectin Therapeutics Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, August 15, 2022 | ||
| 10:59 | | Q2 2022 Galectin Therapeutics Inc Earnings Release |
| Monday, November 14, 2022 | ||
| 13:30 | | Q3 2022 Galectin Therapeutics Inc Earnings Release |
| Friday, December 2, 2022 | ||
| 16:00 | | Galectin Therapeutics Inc Annual Shareholders Meeting |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 21.481 | 16.247 | 13.602 | 13.438 | 23.444 | 30.179 |
| Selling/General/Admin. Expenses, Total | 6.156 | 4.526 | 7.131 | 5.971 | 5.468 | 6.361 |
| Research & Development | 15.325 | 11.721 | 6.471 | 7.467 | 17.976 | 23.818 |
| Operating Income | -21.481 | -16.247 | -13.602 | -13.438 | -23.444 | -30.179 |
| Interest Income (Expense), Net Non-Operating | 0.045 | 0.012 | -0.298 | 0.144 | -0.021 | -0.348 |
| Net Income Before Taxes | -21.436 | -16.235 | -13.9 | -13.294 | -23.465 | -30.527 |
| Net Income After Taxes | -21.436 | -16.235 | -13.9 | -13.294 | -23.465 | -30.527 |
| Net Income Before Extra. Items | -21.436 | -16.235 | -13.9 | -13.294 | -23.465 | -30.527 |
| Net Income | -21.436 | -16.235 | -13.9 | -13.294 | -23.465 | -30.527 |
| Total Adjustments to Net Income | -0.914 | -1.232 | -1.147 | -6.885 | -0.137 | -0.171 |
| Income Available to Common Excl. Extra. Items | -22.35 | -17.467 | -15.047 | -20.179 | -23.602 | -30.698 |
| Income Available to Common Incl. Extra. Items | -22.35 | -17.467 | -15.047 | -20.179 | -23.602 | -30.698 |
| Diluted Net Income | -22.35 | -17.467 | -15.047 | -20.179 | -23.602 | -30.698 |
| Diluted Weighted Average Shares | 29.216 | 35.521 | 39.414 | 52.238 | 57.029 | 58.527 |
| Diluted EPS Excluding Extraordinary Items | -0.76499 | -0.49174 | -0.38177 | -0.38629 | -0.41386 | -0.52451 |
| Diluted Normalized EPS | -0.76499 | -0.49174 | -0.38177 | -0.38629 | -0.41386 | -0.52451 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 6.317 | 8.193 | 8.244 | 7.425 | 9.935 |
| Selling/General/Admin. Expenses, Total | 1.418 | 1.743 | 1.631 | 1.569 | 1.877 |
| Research & Development | 4.899 | 6.45 | 6.613 | 5.856 | 8.058 |
| Operating Income | -6.317 | -8.193 | -8.244 | -7.425 | -9.935 |
| Interest Income (Expense), Net Non-Operating | -0.021 | -0.256 | -0.276 | 0.204 | 0.003 |
| Net Income Before Taxes | -6.338 | -8.449 | -8.52 | -7.221 | -9.932 |
| Net Income After Taxes | -6.338 | -8.449 | -8.52 | -7.221 | -9.932 |
| Net Income Before Extra. Items | -6.338 | -8.449 | -8.52 | -7.221 | -9.932 |
| Net Income | -6.338 | -8.449 | -8.52 | -7.221 | -9.932 |
| Total Adjustments to Net Income | -0.002 | -0.065 | -0.037 | -0.067 | 0.016 |
| Income Available to Common Excl. Extra. Items | -6.34 | -8.514 | -8.557 | -7.288 | -9.916 |
| Income Available to Common Incl. Extra. Items | -6.34 | -8.514 | -8.557 | -7.288 | -9.916 |
| Diluted Net Income | -6.34 | -8.514 | -8.557 | -7.288 | -9.916 |
| Diluted Weighted Average Shares | 57.132 | 58.312 | 59.29 | 59.349 | 59.354 |
| Diluted EPS Excluding Extraordinary Items | -0.11097 | -0.14601 | -0.14432 | -0.1228 | -0.16707 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.11097 | -0.14601 | -0.14432 | -0.1228 | -0.16707 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 15.794 | 3.819 | 8.832 | 48.209 | 29.465 | 41.82 |
| Cash and Short Term Investments | 15.362 | 3.053 | 8.253 | 47.48 | 27.142 | 39.648 |
| Cash & Equivalents | 15.362 | 3.053 | 8.253 | 47.48 | 27.142 | 39.648 |
| Prepaid Expenses | 0.432 | 0.766 | 0.579 | 0.729 | 2.323 | 2.172 |
| Total Assets | 15.795 | 4.161 | 9.006 | 48.467 | 29.6 | 41.827 |
| Property/Plant/Equipment, Total - Net | 0 | 0 | 0 | 0.084 | 0.048 | 0.007 |
| Property/Plant/Equipment, Total - Gross | 0.074 | 0.074 | 0.074 | 0.158 | 0.122 | 0.081 |
| Accumulated Depreciation, Total | -0.074 | -0.074 | -0.074 | -0.074 | -0.074 | -0.074 |
| Intangibles, Net | 0.001 | 0 | 0 | |||
| Total Current Liabilities | 3.78 | 2.968 | 2.108 | 2.82 | 5.399 | 9.033 |
| Accounts Payable | 0.91 | 0.608 | 0.297 | 1.661 | 1.292 | 1.805 |
| Accrued Expenses | 2.802 | 2.292 | 1.512 | 1.093 | 4.042 | 7.163 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.068 | 0.068 | 0.299 | 0.066 | 0.065 | 0.065 |
| Total Liabilities | 3.78 | 2.968 | 2.108 | 2.872 | 5.407 | 39.211 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 29.048 |
| Total Equity | 12.015 | 1.193 | 6.898 | 45.595 | 24.193 | 2.616 |
| Redeemable Preferred Stock | 2.28 | 2.28 | 2.26 | 2.26 | 2.25 | 2.25 |
| Preferred Stock - Non Redeemable, Net | 6.682 | 6.682 | 6.682 | |||
| Common Stock | 0.033 | 0.036 | 0.041 | 0.056 | 0.056 | 0.059 |
| Additional Paid-In Capital | 166.721 | 173.363 | 194.13 | 259.673 | 261.883 | 271.001 |
| Retained Earnings (Accumulated Deficit) | -163.701 | -181.168 | -196.215 | -216.394 | -239.996 | -270.694 |
| Total Liabilities & Shareholders’ Equity | 15.795 | 4.161 | 9.006 | 48.467 | 29.6 | 41.827 |
| Total Common Shares Outstanding | 32.9129 | 35.7894 | 41.1909 | 56.8946 | 57.0771 | 59.3413 |
| Total Preferred Shares Outstanding | 6.88568 | 6.88568 | 6.83568 | 1.32768 | 1.30268 | 1.30268 |
| Other Long Term Assets, Total | 0.342 | 0.174 | 0.174 | 0.087 | ||
| Other Liabilities, Total | 0.052 | 0.008 | 1.13 | |||
| Long Term Debt | 29.048 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 22.794 | 33.334 | 37.998 | 41.82 | 33.507 |
| Cash and Short Term Investments | 20.76 | 31.598 | 36.6 | 39.648 | 31.606 |
| Cash & Equivalents | 20.76 | 31.598 | 36.6 | 39.648 | 31.606 |
| Prepaid Expenses | 2.034 | 1.736 | 1.398 | 2.172 | 1.901 |
| Total Assets | 22.897 | 33.405 | 38.038 | 41.827 | 33.615 |
| Property/Plant/Equipment, Total - Net | 0.038 | 0.028 | 0.018 | 0.007 | 0.108 |
| Other Long Term Assets, Total | 0.065 | 0.043 | 0.022 | ||
| Total Current Liabilities | 4.663 | 6.054 | 8.299 | 9.033 | 9.535 |
| Accounts Payable | 0.382 | 0.924 | 1.917 | 1.805 | 1.906 |
| Accrued Expenses | 4.281 | 5.065 | 6.382 | 7.163 | 7.629 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0.065 | 0 | 0.065 | 0 |
| Total Liabilities | 4.663 | 16.289 | 28.789 | 39.211 | 39.808 |
| Total Long Term Debt | 0 | 9.643 | 19.299 | 29.048 | 29.275 |
| Other Liabilities, Total | 0 | 0.592 | 1.191 | 1.13 | 0.998 |
| Total Equity | 18.234 | 17.116 | 9.249 | 2.616 | -6.193 |
| Redeemable Preferred Stock | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 |
| Common Stock | 0.056 | 0.059 | 0.059 | 0.059 | 0.059 |
| Additional Paid-In Capital | 262.264 | 269.657 | 270.347 | 271.001 | 272.108 |
| Retained Earnings (Accumulated Deficit) | -246.336 | -254.85 | -263.407 | -270.694 | -280.61 |
| Total Liabilities & Shareholders’ Equity | 22.897 | 33.405 | 38.038 | 41.827 | 33.615 |
| Total Common Shares Outstanding | 57.1867 | 59.275 | 59.3413 | 59.3413 | 59.3885 |
| Total Preferred Shares Outstanding | 1.30268 | 1.30268 | 1.30268 | 1.30268 | 1.30268 |
| Long Term Debt | 9.643 | 19.299 | 29.048 | 29.275 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -21.436 | -16.235 | -13.9 | -13.294 | -23.465 | -30.527 |
| Cash From Operating Activities | -16.409 | -15.892 | -10.179 | -10.848 | -20.601 | -24.308 |
| Cash From Operating Activities | 0.007 | 0.001 | 0 | |||
| Non-Cash Items | 2.479 | 1.146 | 4.793 | 1.805 | 1.922 | 2.468 |
| Changes in Working Capital | 2.541 | -0.804 | -1.072 | 0.641 | 0.942 | 3.751 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | 0 | |||
| Cash From Financing Activities | 5.925 | 3.583 | 15.379 | 50.075 | 0.263 | 36.814 |
| Issuance (Retirement) of Stock, Net | 5.925 | 3.583 | 15.379 | 50.469 | 0.263 | 6.814 |
| Net Change in Cash | -10.484 | -12.309 | 5.2 | 39.227 | -20.338 | 12.506 |
| Total Cash Dividends Paid | -0.394 | 0 | ||||
| Other Investing Cash Flow Items, Total | 0 | |||||
| Issuance (Retirement) of Debt, Net | 30 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -6.338 | -14.787 | -23.306 | -30.527 | -9.932 |
| Cash From Operating Activities | -6.382 | -12.359 | -17.357 | -24.308 | -8.042 |
| Non-Cash Items | 0.286 | 1.134 | 2.007 | 2.468 | 0.719 |
| Changes in Working Capital | -0.33 | 1.294 | 3.942 | 3.751 | 1.171 |
| Cash From Financing Activities | 0 | 16.815 | 26.815 | 36.814 | 0 |
| Issuance (Retirement) of Stock, Net | 0 | 6.815 | 6.815 | 6.814 | 0 |
| Net Change in Cash | -6.382 | 4.456 | 9.458 | 12.506 | -8.042 |
| Issuance (Retirement) of Debt, Net | 10 | 20 | 30 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Galectin Therapeutics Inc. Company profile
About Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).
Equity composition
Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US
Income statement
News
3M demerger: MMM spin off Food Safety Business SpinCo merger with Neogen timing and details in full
3M (MMM) has revealed further details about its $5.3bn scheme to spin off its food-safety business. Added to the demerger of its health care products division, 3M is taking steps to lift its stock price.
19:21, 12 August 2022
US and Europe gas prices: What's the impact of heatwaves and hurricanes?
Demand for cooling is soaring in Europe as temperatures climb, adding to market pressure
18:51, 12 August 2022
Small cap index: A ‘small window’ for traders before Wyoming symposium
SWAV, SAIL, SWN, and AR lead Russell 2000 and small company stocks
17:42, 12 August 2022
The Palantir revenue outlook has an upside: here’s why
The Palantir revenue outlook slid this week, but key comments by executives of the enigmatic data software firm point to quiet confidence in a comeback
15:59, 12 August 2022
Oil trading: Asian punters book crude profits amid uncertainty
Conflicting demand forecasts by IEA, OPEC shows uncertainty’s destabilising the market
15:37, 12 August 2022People Also Watch
US Crude Oil Spot
| Long position overnight fee | 0.0139% |
| Short position overnight fee | -0.0312% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 0.03 |
Still looking for a broker you can trust?
Join the 427.000+ traders worldwide that chose to trade with Capital.com
